Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 826 participants.

Also called NCT07090343

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 826 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07090343
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07090343. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-01 (anticipated); primary completion 2030-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
Acronym
REVERSE-TAVR
Condition
Aortic Stenosis
Condition
Heart Failure
Intervention (Drug)
Wegovy ®
Intervention (Drug)
Placebo
Lead sponsor
Leiden University Medical Center (class: other)

Record details

Record id
cardio:ct-nct07090343
Content hash
723a7b9859750533b7e900dd1e814a8f25eb9c86e75e4eb7e3e31b5c60461297